Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1-4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5-8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.
Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. JAMA. 2006;296(21):2555–2560. doi:10.1001/jama.296.21.2558-c
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: